Monte Rosa CMO Filip Janku sells 41,845 shares for $882,203.48 via scheduled 10b5-1 plan
Filip Janku, Chief Medical Officer, executed 2 separate sales totaling 41,845 shares for $882,203.48 on 2026-06-23 and 2026-06-24 through a pre-arranged 10b5-1 trading plan adopted on 2026-03-04. His non-derivative holdings decreased from 101,837 shares to 59,992 shares, though he retains 96,000 and 66,000 stock options, meaning his overall position remains material. The sales occurred as GLUE's stock was +12.8% over the prior 30 days and +40.8% over 90 days, yet the company remains deeply unprofitable with net income of $-44,503,000.00 against quarterly revenue of $4,210,000.00. The scheduled nature of this divestiture limits conclusions about discretionary conviction, but the magnitude of the reduction—41.1% of pre-transaction holdings—during a period of positive stock momentum against persistent operating losses reflects the mechanics of a planned hedge structure.